In the laboratory sector we specialise in proprietary markers for the early diagnosis and management of critical illnesses:
We are playing an increasingly leading role in the fight against the global diabetes epidemic, and the need to keep tight control over blood glucose levels to avoid serious clinical sequelae.
Our proprietary tests and technologies to measure HbA1c, Homocysteine, anti-CCP (for early detection of rheumatoid arthritis) and Active-B12 (for better detection of vitamin B12 deficiency) are driving revenues and there has also been much interest in our newer markers such as Heparin Binding Protein for diagnosis of severe sepsis.
We have a special focus on the strong move of Homocysteine testing away from standard immunoassay techniques to the more convenient clinical chemistry technology, as recently exemplified by our purchase of Catch Inc. in the USA, which has technology and IP in this area.
As new markers are accepted clinically we will explore the possibility of making these tests available at the point of care.
*Products may not be approved for sale in all countries. Please contact us for details of your local distributor or for further details.
A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.
As a general marker of overall health status, few tests carry greater predictive weight than Homocysteine. The amount of Homocysteine in your blood is one of the best independent indicators of how healthy you are.